Doc code: IDS Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
Ormation Disclosure Statement (IDS) Filed
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10551847	
INFORMATION BIOCH COURT	Filing Date		2006-06-23	
INFORMATION DISCLOSURE	First Named Inventor Lin, e		et al.	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1648	
(Not for Submission under or of it 1.00)	Examiner Name	Le, Er	mily M.	
	Attorney Docket Number	er	NBMP-001(SP)	

	U.S.PATENTS Remove										
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D)ate	of cited Document		Releva		ines where es or Relev	
	1	3666646		1972-05	5-30	Lampson, et al					
If you wish to add additional U.S. Patent citation information please click the Add button.											
			U.S.P.	ATENT	APPLIC	CATION PUBI	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		Name of Patentee or Applicant of cited Document		Releva		ines where es or Relev	
	1										
If you wis	If you wish to add additional U.S. Published Application citation information please click the Add button. Add										
FOREIGN PATENT DOCUMENTS Remove											
Examiner Initial*	Cite No	Foreign Document Number ³	1		Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		T 5
	1										
If you wish to add additional Foreign Patent Document citation information please click the Add button Add											
NON-PATENT LITERATURE DOCUMENTS Remove											
Examiner Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T5					

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10551847		
Filing Date		2006-06-23		
First Named Inventor	Lin, e	t al.		
Art Unit		1648		
Examiner Name	Le, Emily M.			
Attorney Docket Number		NBMP-001(SP)		

	1	HAMPNEY, et al., Modified polyriboinosinic-polyribocytidylic acid complex: sustained interferonemia and its hysiological associates in humans, Infect Immun. 1979 September; 25(3): 831-837.				
	2	DE CLERCQ, Degradation of Poly(inosinic acid) · poly(cytidylic acid) [(I)n· (Cn)] by Human Plasma, European Journal of Biochemistry, Volume 93 Issue 1, Pages 165 - 172, 28 Jun 2008.				
	3	GATMAITAN, et al., Modified Polyriboinosiniic-Polyribocytidylic Acid Complex: Induction of Serum Interferon, Fever, and Hypotension in. Rabbits, Antimicrobial agents and chemotherapy, Jan. 1980, Page 49-54, Vol. 17. No.1.				
	4	LEVY, et al., Interferon induction in primates by stabilized polyriboinosinic acid-polyribocytidylic acid: effect of component size, Infect Immun. 1981 November; 34(2): 416-421.				
	5	IACHIDA, et al., Relationship between the molecular size of poly I-poly C and its biological activity, Jpn J Microbiol. 976 Apr;20(2):71-76.				
	6	SHU, et al., Biological function and application of Poly I:C, the First Affiliated Hospital of Xian Medical College.				
	7	SMORODINTSEV, et al., Comparative study of the toxicity of poly G-poly C and poly I-poly C in different objects, Vopr Virusol. 1978 Mar-Apr;(2):201-206.				
	8	STRINGFELLOW, et al., Interferon induction by and toxicity of polyriboinosinic acid [poly(rI)].polyribocytidylic acid [poly (rC)], mismatched analog poly (rI).poly[r(C12Uracil)n], and poly(rI).poly(rC) L-lysine complexed with carboxymethylcellulose, Antimicrob Agents Chemother. 1980 June; 17(6): 988–992.				
	9	TS'O, et al., An Integrated and Comparative Study of the Antiviral Effects and Other Biological Properties of the Polyinosinic Acid-Polycytidylic Acid and Its Mismatched Analogues, Molecular Pharmacology, Vol 12, 299-312, Copyright 1976 by the American Society for Pharmacology and Experimental Therapeutics.				
If you wish to add additional non-patent literature document citation information please click the Add button Add						
EXAMINER SIGNATURE						
Examiner	Examiner Signature Date Considered					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10551847		
Filing Date		2006-06-23		
First Named Inventor Lin, et		t al.		
Art Unit		1648		
Examiner Name	Le, Emily M.			
Attorney Docket Number		NBMP-001(SP)		

¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.